Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Blood (2021) 138 (23): 2337–2346.

https://doi.org/10.1182/blood.2021012206

Published: 2021

Includes: Supplemental data

Journal Articles

Divergent Epigenomes in Pediatric and Adult Acute Myeloid Leukemia Implicate Cell of Origin and Transcriptional Silencing of Immune Responses As Sources of Clinically Relevant Heterogeneity: A Report from the Children's Oncology Group and NCI/COG Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative

Blood (2016) 128 (22): 1046.

https://doi.org/10.1182/blood.V128.22.1046.1046

Published: 2016

Journal Articles

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML

Jessica A. Pollard, Todd A. Alonzo, Michael Loken, Robert B. Gerbing, Phoenix A. Ho, Irwin D. Bernstein, Susana C. Raimondi, Betsy Hirsch, Janet Franklin, Roland B. Walter, Alan Gamis, Soheil Meshinchi

Blood (2012) 119 (16): 3705–3711.

https://doi.org/10.1182/blood-2011-12-398370

Published: 2012

Journal Articles

Functional Polymorphisms in Oxidant Metabolism and DNA Repair Pathways and Risk of Leukemia and Transient Myeloproliferative Disorder in Children with Down Syndrome

Melissa S Rayburg, MD, Mi-Ok Kim, Todd Alonzo, PhD, Robert Gerbing, Gretchen A Radloff, Stella M Davies, Alan Gamis, MD, John Perentesis

Blood (2008) 112 (11): 2947.

https://doi.org/10.1182/blood.V112.11.2947.2947

Published: 2008

Journal Articles

COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML)

Janet Franklin, MD, MPH, Todd Alonzo, PhD, Craig Alan Hurwitz, MD, Robert Gerbing, Franklin Smith, Robert J. Arceci, MD, PhD, James Feusner, MD, Prasad Mathew, MD, Robert Iannone, MD, Soheil Meshinchi, MD, PhD, Robert Lavey, MD, MPH, Joetta D Wallace, RN, Kelly Anderson, RN, Laura Winter, PharmD, Kathleen Glick, BA, Betty Hirsch, MD, Susana C. Raimondi, PhD, Alan Gamis, MD

Blood (2008) 112 (11): 136.

https://doi.org/10.1182/blood.V112.11.136.136

Published: 2008

Journal Articles

Correlation of CD 33 Expression Level with Disease Characteristics and Response to Gemtuzumab Ozogamycin-Containing Chemotherapy in Childhood AML

Jessica A Pollard, Todd Alonzo, PhD, Robert Gerbing, Susana C. Raimondi, PhD, Betsy Hirsch, Janet Franklin, MD, MPH, Alan Gamis, MD, Michael R Loken, Soheil Meshinchi, MD, PhD

Blood (2008) 112 (11): 148.

https://doi.org/10.1182/blood.V112.11.148.148

Published: 2008

Journal Articles

Cell Death Regulatory Gene Expression Correlates with MLL Rearrangement Status and Prognostic Clinical Covariates in Acute Leukemia in Infants.

Alena Y. Zhang, PharmD, PhD, Blaine W. Robinson, PhD, Kajia Kao, PhD, Kathryn Behling, MD, PhD, Meenakshi Devidas, PhD, Todd Alonzo, PhD, Susana C. Raimondi, PhD, Andrew Carroll, PhD, Robert J. Arceci, MD, PhD, Alan Gamis, MD, Stephen P. Hunger, MD, Gregory H. Reaman, MD, Richard C. Harvey, PhD, Cheryl L. Willman, MD, Li-San Wang, PhD, Carolyn A. Felix, MD

Blood (2008) 112 (11): 2255.

https://doi.org/10.1182/blood.V112.11.2255.2255

Published: 2008

Journal Articles

Analysis of JAK3 , JAK2 , and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome

Alice Norton, Chris Fisher, Hui Liu, Qiang Wen, Gina Mundschau, Jose Luis Fuster, Henrik Hasle, Bernward Zeller, David K. Webb, Aengus O'Marcaigh, April Sorrell, Joanne Hilden, Alan Gamis, John D. Crispino, Paresh Vyas

Blood (2007) 110 (3): 1077–1079.

https://doi.org/10.1182/blood-2007-03-080374

Published: 2007

Journal Articles

Uniform Approach Better Defines Natural History of Transient Myeloproliferative Disorder (TMD) in Down Syndrome (DS) Neonates: Outcomes from Children’ Oncology Group (COG) Study A2971.

Mukta Sharma, MD, Todd A. Alonzo, PhD, April Sorrell, MD, Robert B. Gerbing, MA, Joanne M. Hilden, MD, Robert J. Arceci, MD, PhD, Gita Massey, MD, John J. Doyle, MD, Lisa Bayer, CPNP, John P. Perentesis, MD, Julie Ross, PhD, Franklin O. Smith, MD, Russell Brynes, MD, Jerry Hussong, MD, Lois Hathaway, Alan Gamis, MD

Blood (2006) 108 (11): 376.

https://doi.org/10.1182/blood.V108.11.376.376

Published: 2006

Journal Articles

Cyclosporine, Interferon-γ , and Interleukin-2 Immunotherapy Is Tolerable and Induces Autoreactivity in Patients with Recurrent/Refractory Hodgkin Disease Undergoing Autologous Stem Cell Transplantation with BEAM: A COG Study.

Allen Chen, MD, PhD, Allan Hess, PhD, Sharon Gardner, MD, Tanya Trippett, MD, Pedro de Alarcon, MD, Robert Guillerman, MD, Shirley Hogan, PharmD, Joy Mitchell, Alan Gamis, MD, Vicki Massey, MD, Louis S. Constine, MD, Doojduen Villaluna, MS, Richard Sposto, MD, Cindy Schwartz, MD

Blood (2005) 106 (11): 2087.

https://doi.org/10.1182/blood.V106.11.2087.2087

Published: 2005

Journal Articles

Down Syndrome Patients with Relapsed Acute Myelogenous Leukemia.

Thomas W. Loew, M.D., Alan Gamis, M.D., Franklin O. Smith, M.D., Gita V. Massey, M.D., William G. Woods, M.D., Joanne M. Hilden, M.D., Beverly Lange, M.D., Todd A. Alonzo, Ph.D., Myron Chang, Ph.D., Robert B. Gerbing, M.A.

Blood (2004) 104 (11): 4526.

https://doi.org/10.1182/blood.V104.11.4526.4526

Published: 2004

Journal Articles

Induction Therapy Failures in Down Syndrome Patients with Acute Myelogenous Leukemia.

Blood (2004) 104 (11): 4527.

https://doi.org/10.1182/blood.V104.11.4527.4527

Published: 2004

NARROW

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML

Functional Polymorphisms in Oxidant Metabolism and DNA Repair Pathways and Risk of Leukemia and Transient Myeloproliferative Disorder in Children with Down Syndrome

COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML)

Correlation of CD 33 Expression Level with Disease Characteristics and Response to Gemtuzumab Ozogamycin-Containing Chemotherapy in Childhood AML

Cell Death Regulatory Gene Expression Correlates with MLL Rearrangement Status and Prognostic Clinical Covariates in Acute Leukemia in Infants.

Analysis of JAK3 , JAK2 , and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome

Uniform Approach Better Defines Natural History of Transient Myeloproliferative Disorder (TMD) in Down Syndrome (DS) Neonates: Outcomes from Children’ Oncology Group (COG) Study A2971.

Cyclosporine, Interferon-γ , and Interleukin-2 Immunotherapy Is Tolerable and Induces Autoreactivity in Patients with Recurrent/Refractory Hodgkin Disease Undergoing Autologous Stem Cell Transplantation with BEAM: A COG Study.

Down Syndrome Patients with Relapsed Acute Myelogenous Leukemia.

Induction Therapy Failures in Down Syndrome Patients with Acute Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only